Cargando…
MET alterations in advanced pulmonary sarcomatoid carcinoma
Pulmonary sarcomatoid carcinoma (PSC) is a rare subset of NSCLC that accounts for about 0.5-1% of all primary lung carcinoma, and its malignant biological behavior is more aggressive than other pathological types of lung cancer. Recent studies have reported a variety of gene mutations associated wit...
Autores principales: | Gong, Chen, Xiong, Huihua, Qin, Kai, Wang, Jianhua, Cheng, Yi, Zhao, Jing, Zhang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539670/ https://www.ncbi.nlm.nih.gov/pubmed/36212500 http://dx.doi.org/10.3389/fonc.2022.1017026 |
Ejemplares similares
-
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
por: Wen, Yingmei, et al.
Publicado: (2023) -
Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023) -
Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma
por: Sun, Jiachun, et al.
Publicado: (2022) -
Serine-associated one-carbon metabolic reprogramming: a new anti-cancer therapeutic strategy
por: Zhang, Jing, et al.
Publicado: (2023) -
Computed Tomography Features and Clinicopathological Characteristics of Gastric Sarcomatoid Carcinoma
por: Liu, Yi-yang, et al.
Publicado: (2020)